Financial Performance - Revenue for the first half of 2024 was RMB 8,574,214 thousand, a 1.0% increase from RMB 8,492,046 thousand in 2023[10] - Adjusted net profit was RMB 2,544,800 thousand, a decline of 13.0% compared to RMB 2,925,580 thousand in the previous year[10] - Gross profit decreased by 5.9% to RMB 3,349,951 thousand, down from RMB 3,560,634 thousand[10] - The gross profit margin for the first half of 2024 was 39.1%, down from 41.9% in 2023[10] - The group's net profit decreased by 23.9% from approximately RMB 2,337.9 million for the six months ended June 30, 2023, to approximately RMB 1,780.3 million for the same period in 2024, with a net profit margin decline from 27.5% to 20.8%[78] - Basic earnings per share fell by 32.7% from RMB 0.55 for the six months ended June 30, 2023, to RMB 0.37 for the same period in 2024[81] - Adjusted net profit margin decreased to 29.7% in 2024 from 34.5% in 2023[114] - Other income increased by 71.1% to approximately RMB 338.7 million, driven by higher interest income from increased cash balances following the company's listing[66] Project and Development Updates - The total number of ongoing projects increased to 742, with 359 in preclinical development and 311 in early clinical development[15] - The company added four new late-stage clinical and commercialization projects, contributing to growth momentum[15] - The total amount of uncompleted orders as of June 30, 2024, reached USD 20,105 million, including USD 13,000 million in uncompleted service orders and USD 7,105 million in uncompleted potential milestone payment orders[19] - The company has enabled over 550 IND submissions as of the reporting period, demonstrating its commitment to advancing innovative biopharmaceuticals[28] - The company achieved a global production success rate of approximately 98% during the reporting period, with over 72 projects in late-stage clinical and non-COVID commercialization production[11] Strategic Initiatives and Collaborations - The company continues to implement its "Follow and Win Molecules" strategy, which is expected to drive future revenue growth[12] - The company has established strategic collaborations with major pharmaceutical companies, including GSK, BioNTech, and Medigene, to advance new biopharmaceutical technologies[27] - The company continues to enhance its advanced technology platforms to accelerate biopharmaceutical development and production, ensuring it remains a leader in the industry[29] Financial Position and Assets - Total assets as of June 30, 2024, were RMB 56,105,719 thousand, a decrease of 0.8% from RMB 56,575,726 thousand[10] - Total liabilities decreased by 8.7% to RMB 11,464,904 thousand from RMB 12,557,844 thousand[10] - Cash and cash equivalents were RMB 9,153,528 thousand, down 5.3% from RMB 9,669,839 thousand[10] - The company's microbial platform business saw significant growth, with a substantial increase in signed microbial projects and molecules during the reporting period[38] Operational Efficiency and Cost Management - The company continues to implement its WBS management system, resulting in significant cost savings and quality improvements through approximately 60 improvement projects[48] - Sales and marketing expenses grew by 111.7% from approximately RMB 105.4 million for the six months ended June 30, 2023, to approximately RMB 223.1 million for the same period in 2024, representing 2.6% of the group's revenue[70] - Administrative expenses increased by 13.7% from approximately RMB 679.6 million for the six months ended June 30, 2023, to approximately RMB 773.0 million for the same period in 2024, driven by rising employee-related costs and digital solutions[71] Shareholder Information and Equity - As of June 30, 2024, Dr. Li Ge holds 592,902,633 shares, representing 14.28% of the company's total issued shares[150] - The total number of issued shares as of June 30, 2024, is 4,153,165,949[151] - The company has a significant shareholder structure, with Life Science Holdings controlling 584,191,133 shares, equivalent to 14.07% of the total shares[157] - BlackRock, Inc. holds 217,282,290 shares, accounting for 5.23% of the company's total issued shares[157] Risk Management and Compliance - The company emphasizes robust risk management as crucial for efficient operations, actively assessing significant risks including operational, financial, and regulatory risks[132] - The company is closely monitoring the legislative process of the proposed Biosecurity Act in the U.S. and remains committed to compliance with applicable laws and regulations[52] - The company has implemented forward contracts to manage currency risk and adopted hedge accounting for derivatives to mitigate the impact of exchange rate fluctuations on profit and loss[143] Sustainability and Corporate Governance - The company is committed to sustainability, achieving recognition from multiple ESG rating agencies, including an AAA rating from MSCI ESG[40] - The company plans to continue enhancing its corporate governance practices to ensure compliance with governance codes[127] - The independent auditor has reviewed the interim financial data, confirming that the interim results and report comply with applicable accounting standards and regulations[131]

Investment Rating - The report maintains an "Outperform" rating for WuXi Biologics (02269 HK) [1][4] Core Views - Revenue remained stable in H1 2024, but net profit declined YoY [1][5] - The "Follow and Win the Molecule" strategy continues to advance, with total backlog maintaining at historical highs [1][7] - Global strategic layout upgrades are driving international business expansion [1][9] - Breakthroughs in drug discovery and production technologies are accelerating [1][10] Financial Performance - H1 2024 revenue reached RMB 8 574 million (+1 0% YoY, +7 7% excluding COVID-19 projects) [1][5] - Net profit attributable to shareholders was RMB 1 499 million (-33 9% YoY) [1][5] - IFRS adjusted net profit was RMB 2 540 million (-13 0% YoY) [1][5] - Sales expense ratio increased to 2 6% (+1 4pp), management expense ratio rose to 9 0% (+1 0pp), while financial expense ratio decreased to 0 8% (-0 1pp) [1][5] Business Development - 61 new projects signed in H1 2024 (+32 6% YoY), including 9 "Win the Molecule" projects [1][7] - Total backlog reached $20 105 billion as of June 30 2024 [1][7] - Total ongoing projects reached 742 (+21 0% YoY) [1][7] - Significant expansion across all biologics pipelines: monoclonal antibodies (316 projects, +13 7%), bispecific/multispecific antibodies (123 projects, +17 1%), antibody-drug conjugates (167 projects, +51 8%), fusion proteins (76 projects, +13 4%), other proteins (37 projects, +8 8%), and vaccines (23 projects, +21 1%) [1][7][8] Global Expansion - Capacity expansion in New Jersey, USA: added 2000L drug substance capacity [1][9] - Completed first PPQ project in Dundalk, Ireland [1][9] - MFG20 facility launched in Hangzhou, China with three 5000L single-use bioreactors [1][9] - DP2 and DP5 facilities in Wuxi, China successfully passed FDA pre-approval inspections [1][9] Technological Advancements - CD3/WuXiBodyTM and WuXiUPTM platforms successfully produced CN201 molecule, a potential best-in-class CD3xCD19 antibody [1][10] - Next-generation production platform WuXiUITM increased protein yield by 3-6 times [1][10] Financial Projections - 2024-2026 net profit forecast maintained at RMB 3 823/4 483/5 321 million, with YoY growth of 12 4%/17 3%/18 7% [1][11] - 2024-2026 revenue projected at RMB 18 145/20 852/24 129 million, with YoY growth of 6 5%/14 9%/15 7% [2] - EPS expected to be RMB 0 90/1 05/1 25 for 2024-2026 [2]

Investment Rating - The report maintains an "Accumulate" rating for WuXi Biologics (2269) [4][5]. Core Views - The company is actively advancing its "Winning Molecules" strategy, with new projects exceeding expectations and strong growth momentum in non-COVID business. The overseas capacity is continuously being established, indicating a positive long-term outlook for the company [4][5]. Financial Summary - Revenue for 2023 is projected at 17,051 million RMB, with a growth rate of 12% compared to the previous year. The revenue for 2024 is expected to grow by 5% to 20,521 million RMB, and by 18% to 24,282 million RMB by 2026 [4]. - Adjusted net profit for 2024 is revised down to 49.19 billion RMB, with EPS adjusted to 1.18 RMB [5]. - The gross profit margin is reported at 39.07%, reflecting a decrease of 2.9 percentage points due to reduced milestone revenue and the ramp-up of new facilities [5]. Project and Capacity Growth - In the first half of 2024, the company added 61 new projects, with a total of 201 billion USD in uncompleted orders, supporting future revenue growth [5]. - The North American region saw a revenue increase of 27.3%, accounting for 58.4% of total revenue, highlighting strong customer retention [5]. Market Performance - The current stock price is reported at 11.22 HKD, with a 52-week price range between 10.26 and 51.00 HKD [3][4].

Investment Rating - The report does not specify a clear investment rating for WuXi Biologics (2269.HK) [1] Core Insights - WuXi Biologics reported a revenue of 85.7 billion RMB for H1 2024, a slight increase of 1% year-on-year, while the net profit attributable to shareholders decreased by 33.9% to 15 billion RMB [2] - Non-COVID related revenue grew by 7.7% year-on-year, with clinical stage revenues showing resilience despite a high base from the previous year [2] - The company added 61 new non-COVID projects in H1 2024, indicating a recovery in project additions after a slowdown in Q1 2023 [2] - The total backlog of uncompleted orders reached approximately 20.1 billion USD, with a significant portion expected to contribute to future revenue growth [2] Summary by Sections Financial Performance - For H1 2024, WuXi Biologics achieved a revenue of 85.7 billion RMB, with a year-on-year growth of 1%. The adjusted net profit was 25.4 billion RMB, down 13% year-on-year [2] - The company expects net profits for 2024, 2025, and 2026 to be 34.8 billion RMB, 40.1 billion RMB, and 48.2 billion RMB respectively, with corresponding EPS of 0.84, 0.97, and 1.16 RMB [3] Project Development - The number of new projects added in H1 2024 was 61, compared to 46 in H1 2023, reflecting a recovery in project activity [2] - The company has a strong pipeline with 56 clinical stage projects and 16 non-COVID commercialization projects, which are expected to drive future revenue [2] Capacity Expansion - WuXi Biologics is expanding its manufacturing capabilities with new facilities in Singapore and Ireland, aiming for significant production capacity by 2025 [3] - The company operates a global network of drug discovery and development centers, enhancing its ability to support partners [3]

Investment Rating - The report maintains a neutral rating for WuXi Biologics (2269 HK) with a target price of HKD 12.30, indicating a potential upside of 18.3% from the current closing price of HKD 10.40 [1][2][6]. Core Views - The company's 1H24 performance met expectations, with revenue growth of 1.0% year-on-year, excluding COVID-related revenue, which reflects a growth of 7.7%. However, the adjusted net profit decreased by 20.7% due to high base effects from 1H23 and increased SG&A expenses [1][2]. - The report highlights that the short-term uncertainties in the industry and external environment remain significant risks, leading to a downward revision of the earnings forecast for 2024-2026 by 4-19% [1][2]. - The company expects to receive approximately RMB 500 million in large payments in 2H24, which is anticipated to improve operational efficiency and revenue growth in the latter half of the year [1][2]. Financial Summary - Revenue projections for 2024E are set at RMB 17,989 million, with a decrease of 0.8% from previous estimates. For 2025E and 2026E, revenues are projected at RMB 20,710 million and RMB 23,701 million, reflecting decreases of 9.0% and 8.3% respectively [2][7]. - The adjusted net profit for 2024E is forecasted at RMB 5,019 million, down 3.6% from prior estimates, with further declines of 18.6% and 17.5% for 2025E and 2026E [2][7]. - The gross profit margin is expected to decline to 39.1% in 2024E, down from 41.6% in the previous forecast, indicating a decrease of 2.5 percentage points [2][7]. Order and Capacity Utilization - In 1H24, the company secured 61 new orders, with a strong momentum in late-stage projects, including 9 "winning molecule" projects. The company anticipates signing additional contracts by the end of the year [1][2]. - The report notes that the capacity utilization rate is expected to improve steadily, particularly with the ramp-up of production in Ireland, which is projected to break even by 1H25 and achieve an 80% utilization rate by 2026 [1][2].

Investment Rating - The report maintains a "Neutral" rating for WuXi Biologics (2269 HK) with a target price adjusted to HKD 10.20 from HKD 13.00 [2][4][11]. Core Views - The company's performance in the first half of 2024 was below expectations, with revenue increasing by only 1.0% year-on-year to RMB 8.57 billion. Excluding COVID-related projects, revenue growth was 7.7%. Shareholder net profit decreased by 33.9% to RMB 1.50 billion, reflecting a 20.7% decline in adjusted net profit to RMB 2.25 billion [1][2]. - The report highlights challenges in the domestic market, with revenue from China declining by 20.9% to RMB 1.42 billion. The absence of significant prepayment transactions, which contributed approximately RMB 300 million in gross profit in the previous year, further impacted profitability [1][2]. - The report anticipates continued challenges in the short term, leading to downward adjustments in revenue and profit forecasts for 2024-2026. Revenue estimates were reduced by 2.9%, 9.8%, and 12.9%, while shareholder net profit forecasts were cut by 14.6%, 18.4%, and 20.8% for the same periods [2][3]. Summary by Sections Financial Performance - For the first half of 2024, total revenue was RMB 8.57 billion, with a 1.0% year-on-year increase. Adjusted net profit was RMB 2.25 billion, down 20.7% year-on-year [1]. - The company signed 61 new projects in the first half, with 52 being lower-fee preclinical projects, indicating a slower revenue recovery [2][3]. Revenue and Profit Forecasts - Revenue forecasts for 2024, 2025, and 2026 have been adjusted to RMB 17.448 billion, RMB 19.320 billion, and RMB 21.230 billion, respectively, reflecting a downward adjustment of 2.9%, 9.8%, and 12.9% [3][7]. - Shareholder net profit forecasts for the same years are now RMB 3.132 billion, RMB 4.005 billion, and RMB 4.617 billion, with reductions of 14.6%, 18.4%, and 20.8% [3][7]. Market Conditions - The report notes that the recovery of the Chinese market is slower than expected, with significant challenges in financing for the healthcare sector affecting demand for research outsourcing services [2][3]. - The U.S. market, which accounted for 58.4% of revenue in the first half, is also under scrutiny due to potential impacts from the U.S. Biologics Safety Act [2][3].

Investment Rating - The report maintains a "Buy" rating for WuXi Biologics [1][2] Core Views - WuXi Biologics reported a revenue of 8.574 billion RMB for the first half of 2024, a year-on-year increase of 1.0%, with non-COVID revenue growth at 7.7%. The net profit attributable to shareholders was 1.499 billion RMB, a decline of 33.9% year-on-year, while adjusted net profit was 2.545 billion RMB, down 13.0% year-on-year [1] - The company has seen a rapid increase in new projects, with 61 new projects signed in the first half of 2024, approximately half of which are from the United States. The total number of projects reached 742 [1] - The company is actively expanding its global production capacity, with significant developments in its Ireland, Hangzhou, Singapore, and Cranbury facilities [1] - Customer retention remains high, with a total unfulfilled order amount of 20.11 billion USD as of the first half of 2024, indicating strong future revenue potential [1] Summary by Sections Financial Performance - Revenue for the first half of 2024 was 8.574 billion RMB, with a 1.0% increase year-on-year. Non-COVID revenue grew by 7.7%. The net profit attributable to shareholders was 1.499 billion RMB, down 33.9% year-on-year, while adjusted net profit was 2.545 billion RMB, a decrease of 13.0% [1] - Forecasted revenues for 2024-2026 are 18.014 billion RMB, 20.256 billion RMB, and 22.833 billion RMB, with growth rates of 5.7%, 12.4%, and 12.7% respectively [2] Project Development - The company signed 61 new projects in the first half of 2024, with about half from the U.S. The total number of projects reached 742, with significant contributions expected from late-stage clinical and commercial projects [1] - The company’s Ireland facility is seeing strong commercial demand, with plans for further capacity expansion [1] Capacity Expansion - The Ireland facility's MFG6 Phase I has completed its first PPQ, with Phase II expected to commence production this year. The Hangzhou facility is installing three 5000-liter single-use bioreactors, expected to be GMP compliant by the end of 2024 [1] - The company plans to invest approximately 4.8 billion RMB in capital expenditures for 2024, primarily for facility expansions in the U.S. and other regions [1] Customer Retention and Future Orders - Customer retention remains high, with a total unfulfilled order amount of 20.11 billion USD, indicating a strong pipeline for future revenue [1] - Recent agreements, such as the acquisition of a client by Merck for a significant upfront payment, highlight the company's strong position in the market [1]

Investment Rating - The report maintains a "Hold" rating for WuXi Biologics (2269.HK) and lowers the target price to HKD 18.5 from HKD 20 [2][8]. Core Views - The company's 1H24 revenue is broadly in line with expectations, but the adjusted net profit is below expectations due to lower gross margins and higher SG&A expenses. The company maintains its guidance for 2024, expecting high single-digit growth in both revenue and adjusted net profit [2][8]. - The report highlights that the preclinical revenue is growing the fastest, with a 9.2% YoY increase, driven by a recovery in early-stage biopharma financing in Europe and the US. The late-stage clinical revenue also shows a positive trend with an 11.7% YoY increase [2][8]. - The impact of the Biosecurity Act on new project signings has been limited, primarily affecting client decision-making timelines rather than the number of new projects [2][8]. Summary by Sections Financial Performance - 1H24 revenue was RMB 85.7 billion, a 1% increase YoY, while adjusted net profit was RMB 22.5 billion, down 20.7% YoY. The gross margin was 39.1%, down 2.9 percentage points YoY [2][10]. - The company reported a net profit margin of 26.2%, down 7.2 percentage points YoY, attributed to declining gross margins and increased SG&A expenses [2][10]. Revenue Breakdown - By revenue type, preclinical revenue grew 9.2% YoY, while early clinical revenue saw a slight decline. Late-stage clinical revenue recorded an 11.7% increase YoY [2][10]. - The report anticipates accelerated growth in all clinical stages in the second half of the year, with significant contributions expected from new project signings [2][10]. Market Outlook - The company expects to achieve a revenue growth of approximately 5% for the full year 2024, with a target adjusted net profit margin that may face challenges due to overseas operational costs [2][10]. - The report notes that North America remains the fastest-growing region for revenue, with a 27.5% YoY increase, while China experienced a decline of 20.9% YoY [2][10].

Investment Rating - The report maintains a "Buy" rating for WuXi Bio, reflecting a potential upside in the stock price despite geopolitical uncertainties [1]. Core Insights - WuXi Bio reported a revenue of RMB 8.57 billion for the first half of fiscal year 2024, representing a year-on-year growth of 1.0%. The adjusted net profit attributable to the parent company was RMB 2.25 billion, a decline of 20.7% year-on-year [1]. - The company has confirmed its full-year guidance for 2024, expecting both revenue and adjusted net profit to achieve high single-digit growth [1]. - Strong demand from overseas clients is evident, with 61 new integrated projects added in the first half of 2024, including 52 preclinical and 5 I/II clinical projects [1]. - The bioconjugate business has emerged as a significant growth driver, with WuXi XDC's revenue increasing by 68% and adjusted net profit soaring by 147% in the first half of 2024 [1]. Summary by Sections Financial Performance - Revenue for FY 2024 is projected at RMB 17.86 billion, with a year-on-year growth rate of 4.9% [2]. - Adjusted net profit for FY 2024 is estimated at RMB 4.51 billion, reflecting a decline of 4.1% year-on-year [2]. - The company’s earnings per share (adjusted) for FY 2024 is expected to be RMB 1.09, with a projected P/E ratio of 8.8x [2][8]. Market Dynamics - North America accounted for 58.4% of total revenue in the first half of 2024, with a year-on-year growth of 27.5%, primarily driven by U.S. clients [1]. - The total order backlog remained stable at USD 20.11 billion, with a 4% growth over three years [1]. Valuation - The target price has been adjusted from HKD 18.32 to HKD 13.58, indicating a potential decline of 30.6% from the current price of HKD 10.40 [2]. - The report utilizes a 10-year DCF model with a WACC of 10.95% and a terminal growth rate of 2.0% [1][9].

Investment Rating - Maintain BUY with a target price of HK$13.58, down from the previous target price of HK$18.32, indicating a potential upside of 30.6% from the current price of HK$10.40 [2][3]. Core Insights - WuXi Biologics reported a revenue of RMB8.57 billion for 1H24, reflecting a 1.0% year-over-year increase, while adjusted attributable net income decreased by 20.7% year-over-year to RMB2.25 billion [2]. - The company added 61 integrated projects in 1H24, the second-highest in its history, indicating strong demand recovery from overseas customers, particularly in North America where revenue grew by 27.5% year-over-year [2]. - The bioconjugate business, WuXi XDC, saw a significant revenue increase of 68% year-over-year in 1H24, with adjusted net profit surging by 147% year-over-year [2]. - Despite geopolitical uncertainties, management has reaffirmed its full-year guidance for 2024, expecting high-single-digit growth in both revenue and adjusted attributable net income [2]. Financial Summary - For FY24E, revenue is projected at RMB17.863 billion, with a year-over-year growth of 4.9%, while adjusted net profit is expected to decrease by 4.1% to RMB4.508 billion [3][7]. - The company’s revenue growth is forecasted to accelerate in FY25E and FY26E, with expected increases of 11.7% and 12.7% respectively [3][7]. - The adjusted EPS for FY24E is estimated at RMB1.09, with a consensus EPS of RMB0.92 for the same period [3][8]. Valuation Metrics - The adjusted P/E ratio is projected to be 8.8x for FY24E, decreasing to 7.0x by FY26E, indicating a potentially undervalued stock [3][11]. - The DCF valuation suggests a terminal value of RMB87.569 billion, with a WACC of 10.95% and a terminal growth rate of 2.0% [9].